PATENT CLAIM ANALYSIS

Application Number: 16002704
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["530", "324000"]

Abstract:
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th 2  immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.

Claim (Index 21):
A method of treating or ameliorating a disorder, comprising administering to a subject in need thereof a composition comprising a human tear lipocalin mutein or a fragment, variant, fusion protein or conjugate thereof that is capable of inhibiting IL-4 and/or IL-13 from binding to their respective receptors, wherein said disorder is associated with an increase of the Th2 immune response, wherein said lipocalin mutein or fragment thereof has at least 75% sequence identity to the amino acid sequence of the mature human tear lipocalin (SEQ ID NO: 1), wherein said lipocalin mutein or fragment thereof has the following amino acid residues at amino acid positions corresponding to numbering of amino acid positions of mature human tear lipocalin (SEQ ID NO: 1): Ser at amino acid position  26 , Arg at amino acid position  27 , Cys at amino acid position  28 , Arg at amino acid position  30 , Ala at amino acid position  31 , Val at amino acid position  32 , Tyr at amino acid position  33 , Asn at amino acid position  34 , Phe at amino acid position  53 , Ala at amino acid position  55 , Gln at amino acid position  56 , Arg at amino acid position  57 , Lys at amino acid position  58 , Trp at amino acid position  61 , Lys at amino acid position  63 , Tyr at amino acid position  64 , Leu at amino acid position  66 , Ser at amino acid position  80 , Arg at amino acid position  83 , Leu at amino acid position  104 , Cys at amino acid position  105 , Pro at amino acid position  106 , and Gln at amino acid position  108 ;\n wherein said lipocalin mutein or a fragment, variant, fusion protein or conjugate thereof is capable of exhibiting in vivo therapeutic activity in a subject.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.56579
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14364449', '15367680', '12309820', '14981589', '13702792']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6968289388680228
- 35 USC 102 Novelty (BERT): 0.6579027846692169
- Combined Prediction Score: 0.6929363234481422
- Mean Citation Score: 497.254174
- Max Citation Score: 667.0369
- Similarity Product: 603.9359898624359

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test